GlassScriptPhysician profile
Matthew S Fine
NPI 1164686606
$3,176.33
in general payments reported to CMS, 2019-2025
29 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $189 · 2021: $131 · 2022: $388 · 2023: $602 · 2024: $449 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $323.62 | 2019-2021 | |
| Coloplast Corp | $320.61 | 2019-2025 | |
| Teleflex LLC | $241.94 | 2023-2025 | Barrigel, Urolift |
| C. R. Bard, INC. & Subsidiaries | $234.01 | 2019-2024 | Bard Urinary Drainage Bag, Purewick Female External Catheter |
| Allergan, INC. | $213.40 | 2019-2020 | |
| Procept Biorobotics Corporation | $210.51 | 2024-2025 | Aquabeam System |
| Axonics, INC. | $191.03 | 2023 | Axonics |
| Medtronic, INC. | $186.14 | 2022-2023 | Interstim |
| Laborie Medical Technologies Corp. | $143.99 | 2022-2025 | Esense 7fr Abdominal Catheter |
| Astellas Pharma US INC | $131.85 | 2022-2023 | Myrbetriq |
| Tolmar, INC. | $100.98 | 2023-2025 | Jatenzo, Eligard |
| Neotract INC. | $96.63 | 2019 | |
| Myriad Genetic Laboratories, INC. | $78.73 | 2021-2024 | Prolaris |
| Antares Pharma, INC. | $72.76 | 2022-2023 | Nocdurna, Xyosted, Tlando |
| Stryker Corporation | $68.68 | 2025 | Mako |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $65.06 | 2019 | |
| Halozyme INC | $64.54 | 2023 | |
| Mission Pharmacal Company | $57.14 | 2023-2024 | Uribel, Uribel Tabs |
| Abbvie INC. | $53.17 | 2020-2024 | |
| Endo USA, INC. | $52.87 | 2025 | Xiaflex |
| Hologic Sales and Service, LLC | $51.74 | 2020-2025 | Aptima |
| Boston Scientific Corporation | $49.46 | 2025 | Ams 700, Lithovue |
| Olympus America INC. | $38.78 | 2023 | Itind System |
| Telix Pharmaceuticals | $30.87 | 2025 | Illuccix |
| Dendreon Pharmaceuticals LLC | $27.32 | 2025 | Provenge |
| Tolmar Pharmaceuticals, INC. | $20.18 | 2022 | |
| Sumitomo Pharma America, INC. | $18.85 | 2023 | Gemtesa |
| 180 Medical, INC. | $16.02 | 2024 | |
| Therapeuticsmd, INC. | $15.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.